InterMune Gets Europe Approval Backing For Lung Drug

NEW YORK -(Dow Jones)- InterMune Inc. (ITMN) obtained a key recommendation that should lead to European approval of its drug Esbriet for the fatal lung disease called idiopathic pulmonary fibrosis, news that more than doubled the value of the Brisbane,…

gesamten Artikel lesen zurück mit ESC